There are currently 98 active clinical trials seeking participants for Head and Neck Cancer research studies. The states with the highest number of trials for Head and Neck Cancer participants are California, Ohio, Pennsylvania and New York.
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
NCT07085091
Recruiting
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: START Midwest, Grand Rapids, Michigan +3 locations
Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck Cancer, Esophageal Squamous Cell Carcinoma (ESCC)
Register for Updates
ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy
NCT05318027
Recruiting
Evaluate the feasibility of using a chatbot combined with continuous activity monitoring to proactively identify, appropriately triage and help manage patients' symptoms during cancer treatment Determine whether such an early outpatient clinic-based intervention can decrease rates of excess triage visits Correlate changes in activity and early symptom management to emergency department visits, unplanned inpatient hospitalizations and treatment breaks
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Lung Cancer, Gastrointestinal Cancer, Head and Neck Cancer
Register for Updates
Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer
NCT06627270
Recruiting
The goal of this phase II single arm clinical study is to evaluate the effect of antibiotics (metronidazole) and oral chlorhexidine (CHX) in reducing the bacteria load within tumors of patients undergoing surgery for oral cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Oral Squamous Cell Carcinoma, Oral Cancer, Head and Neck Cancer, Head and Neck Carcinoma
Register for Updates
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
NCT04722523
Recruiting
The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Head and Neck Cancer, Head Cancer, Head Cancer Neck, Neck Cancer, Head and Neck Squamous Cell Carcinoma, HNSCC
Register for Updates
Jump: MR Simulation For Radiation Therapy Master Protocol
NCT04545957
Recruiting
This is a master protocol for a prospective Phase I-II study evaluating feasibility and efficacy of incorporating magnetic resonance imaging (MRI) simulation into the planning of radiation treatments.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Brigham and Women Hospital, Boston, Massachusetts +1 locations
Conditions: Prostate Cancer, Recurrent Adenocarcinoma, Liver Cancer, Head and Neck Cancer
Register for Updates
Evaluation of Improved Onboard Patient Imaging
NCT06187103
Recruiting
The primary objective of radiation therapy is to deliver a therapeutic dose of radiation precisely to the target while minimizing exposure to healthy surrounding tissues. Image-guided radiation therapy (IGRT) involves acquiring cone beam computed tomography (CBCT) scans just before or during treatment sessions. By comparing the CBCT images with the reference images from the treatment planning process, clinicians can make necessary adjustments to ensure precise targeting and account for any chang... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of Maryland Medical Center, Baltimore, Maryland
Conditions: Head and Neck Cancer, Breast Cancer, Upper Gastrointestinal Cancer, Lung Cancer, Pelvic Cancer
Register for Updates
Training Swallowing Initiation During Expiration
NCT05278039
Recruiting
Head and neck cancers have escalated to epidemic levels in the United States, and survivors are suffering from life-long, devastating swallowing disorders with limited therapeutic options. This clinical trial investigates a novel swallowing treatment that trains initiation of swallowing during the expiratory phase of respiration to improve swallowing safety and efficiency.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois +1 locations
Conditions: Head and Neck Cancer, Dysphagia, Oropharyngeal Dysphagia, Oropharynx Squamous Cell Carcinoma
Register for Updates
Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
NCT06607406
Recruiting
The goal of this clinical trial is to determine whether accelerated radiotherapy (involving 6 treatments per week) is better than standard radiotherapy (involving 5 treatments per week) at treating cancer of the head and neck when initiated more than 6 weeks after surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/16/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina +2 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma HNSCC
Register for Updates
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
NCT05816785
Recruiting
The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery to remove your tumor or radiation or chemoradiation treatment of your primary cancer. Participants will undergo a research blood draw and a research biopsy as part of the screening process, and will... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Register for Updates
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750
Recruiting
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/07/2025
Locations: Hoag Cancer Center, Irvine, California +78 locations
Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
Register for Updates
NT219 Combined With Standard of Care Biologic Therapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT06919666
Recruiting
Fixed dose NT219 weekly plus pembrolizumab every 3 weeks or cetuximab weekly to be continued until progression, unacceptable toxicity, or investigator or participant decision.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Universtiy of Colorado Hospital, Aurora, Colorado +1 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients
NCT05658731
Recruiting
The goal of this trial is to determine whether it is possible to minimize radiation dose to parts of the brain that are important for thinking and learning in children who require radiation to treat their tumor, and if this will help reduce neurocognitive (thinking and learning) impairments in these patients. Patients with newly diagnosed brain or head and neck tumors who are having radiation therapy will have neurocognitive testing and MRI imaging (both research and for regular care) done as p... Read More
Gender:
ALL
Ages:
Between 1 year and 26 years
Trial Updated:
06/30/2025
Locations: Sibley Memorial Hospital, Washington, District of Columbia +1 locations
Conditions: Brain Tumor, Head and Neck Cancer
Register for Updates